EpiPen maker Mylan Pharmaceuticals might be hit with a subpoena by the House Committee on Oversight and Government Reform because lawmakers say the company has been dragging its feet in turning over documents related to EpiPen pricing. This is just latest reaction to the price of EpiPen jumping more than 500% in a decade. A two-pack now costs $608.
Rep. Jason Chaffetz (R-Ut.) and Rep. Elijah E. Cummings (D-Md.) expressed their frustration with Mylan in a letter they sent to the company on February 3. “Despite numerous verbal and written requests by committee staff, Mylan continues to refuse to produce specific documents and communications the committee requires.” The letter was sent to Mylan’s lawyer Jonathan Su of the Latham & Watkins law firm.
Mylan has given the committee some documentation, but nowhere near the amount that lawmakers requested. They want Mylan’s “full and complete cooperation.” The committee wants all prior requests for information to be fulfilled by February 28, citing letters that lawmakers sent to Su on August 29 and September 30.
Lawmakers charge that Mylan also refuses to provide information about Medicaid rebate payments, despite numerous requests. “Your client’s ongoing refusal to provide this information creates the impression that Mylan is attempting to conceal information about its Medicaid rebate payments from the committee.”
The committee issued this warning: “Mylan must comply with all the committee’s requests for documents and communications and must do so in a timely manner. Anything less than a complete and timely cooperation may result in a subpoena duces tecum and an invitation to testify on all outstanding requests.”